In this exclusive interview, Dr Hank Mansbach, Chief Medical Officer of 89bio discusses clinical development of FGF21 therapy to treat fatty liver disease.
Following the recent announcement of topline results from 89bio’s Phase IIb trial, ENLIVEN, evaluating FGF21 analogue pegozafermin for nonalcoholic steatohepatitis (NASH), a serious liver condition, EPR spoke with Dr Hank Mansbach, the company’s Chief Medical Officer.
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.
What you’ll discover:
Key trends shaping the pharmaceutical formulation sector
Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
Can’t attend live? No worries – register to receive the recording post-event.
NASH currently has no approved treatments. Caused by excess fat, it is referred to as the ‘silent killer’, as most affected individuals don’t exhibit symptoms until liver damage has already occurred.
According to GlobalData, competition to develop a first-to-market drug for NASH is strong. 89bio is one of several companies advancing treatments. While its focus is on pegozafermin, a fibroblast growth factor 21 (FGF21) analogue, other treatments have gained momentum in the race to commercialisation. An example is resmetirom, a selective thyroid hormone receptor-β agonist. This treatment decreases hepatic steatosis and circulating lipids.
In this Q&A, Dr Mansbach elaborates on how FGF21 analogues may work to address the liver manifestations, but also help manage the underlying causes of the disease. He also shares key data from the ongoing Phase IIb clinical trial, and discusses the broader challenges of developing novel therapies in the NASH space.
How does pegozafermin work in potentially treating NASH?
In NASH, excess fat in the liver can lead to progressive disease, including inflammation, liver cell injury and fibrosis, which are associated with increased risk for cardiovascular disease and liver morbidity and mortality.
Pegozafermin is a highly potent fibroblast growth factor 21 (FGF21) analogue. It was engineered using a unique, proprietary glycoPEGylated technology to prolong the biological activity (half-life), while maintaining the efficacy of native FGF21, a metabolic hormone.
FGF21 regulates energy expenditure and glucose and lipid metabolism. It plays multiple roles in the body, such as reducing the formation of new fat in the liver and lowering systemic levels of triglycerides (TGs) in the blood.
FGF21 analogues may represent the most promising class of drugs to treat NASH because they not only address the liver manifestations, but also help manage the underlying causes of the disease”
FGF21 analogues may represent the most promising class of drugs to treat NASH because they not only address the liver manifestations, but also help manage the underlying causes of the disease such as insulin resistance, dyslipidemia and excessive body weight which result in excess fat deposition in the liver.
Data from clinical trials to-date suggests that pegozafermin could reduce hepatic fat and fibrosis. Pegozafermin also has a favourable safety and tolerability profile, with few gastrointestinal (GI) side effects. This is important for a condition that requires chronic treatment, as poor GI tolerability could adversely affect patients’ quality of life, adherence to treatment and clinical outcomes.
pegozafermin’s long half-life allows convenient weekly or every-two-week dosing”
Additionally, pegozafermin’s long half-life allows convenient weekly or every-two-week dosing. Therefore, it could be beneficial for adoption and compliance of injectable therapies for patients living with this chronic, progressive and generally asymptomatic liver disease.
How does pegozafermin differ to the current standard of care for NASH?
With no approved treatments for NASH, patients must rely on treatment of co-morbidities and lifestyle changes, including diet, exercise and medications to induce weight loss and improve glycemic control.
In the European Union, NASH affects nearly 10 million people and is expected to increase by more than 40 percent by 2030. It is becoming the leading cause for liver transplants. The ability to reverse disease progression, resulting in fewer liver transplants and treatments, could save the healthcare system billions annually.
Tell us about the technology used to develop pegozafermin…
Our proprietary glycoPEGylation technology increases the half-life of native FGF21 from less than two hours for the native hormone to between 55 and 100 hours, allowing for weekly or every-other-week dosing. Our analogue maintains potency against the important FGF receptors: FGFR1c, FGFR2c and FGFR3c which play an important role in the underlying causes of both severe hypertriglyceridemia (SHTG) and NASH.
What data highlights can you share from the trial?
ENLIVEN is a Phase IIb trial designed to evaluate the safety and efficacy of weekly (15mg and 30mg) or every two-week (44mg) pegozafermin for patients with fibrosis stage F2 – F3 NASH and NAS ≥ 4 for 48 weeks.
Results from a Phase Ib/IIa, proof-of-concept study in NASH, demonstrated:
Pegozafermin was generally well tolerated and had beneficial therapeutic effect in reducing liver fat and improving markers of liver injury, fibrosis and lipids
Statistically significant absolute reductions in hepatic fat fraction at week 13 with pegozafermin administered every week or every two weeks compared to placebo
Up to 88 percent of patients had at least a 30 percent reduction in hepatic fat fraction. This has been shown to correlate with reduced fibrosis progression
Improvements in liver transaminases (measures of liver injury) and lipids, as well as improvement in fibrosis and NASH resolution (in a small cohort of biopsy-proven NASH patients) were observed with pegozafermin compared to placebo.
What was the main challenge in developing pegozafermin?
One of the most challenging things in developing new and novel therapies for NASH, is the fact that we are working in uncharted territories.
Greater focus on new mechanisms for lowering low-density lipoprotein (LDL) cholesterol, has resulted in less attention to learning more about how SHTG develops and how to treat it. We knew the road to developing an effective treatment for liver and cardiometabolic diseases like these wouldn’t be easy. But in the last four years alone, we have shown proof of concept and advanced two indications to the point of late-stage clinical studies, and this is just the beginning.
In ten years, what could be the main treatment modality for cardiometabolic diseases?
In ten years, we are hopeful that the millions of patients with liver and cardiometabolic diseases like SHTG and NASH have effective treatment options that will address the underlying cause of their disease.
Based on data to-date we know that FGF21 analogues address liver manifestations and impact glycaemic, TGs, lipid and body weight control, which results in excess fat deposition in the liver. We are encouraged by the potential of pegozafermin as a highly potent FGF21 analogue. We believe it could become a mainstay treatment option and transform the treatment paradigm for both NASH and SHTG.
About the authors
Dr Hank Mansbach is Chief Medical Officer of 89bio. Dr Mansbach has more than 20 years of clinical, regulatory, and medical affairs experience working across all stages of product development in a wide range of disease states. Most recently, Dr Mansbach was head of metabolic and neurology global clinical development at Ultragenyx. There, he led clinical development for several programmes on rare inborn errors of metabolism. Before Ultragenyx, Dr Mansbach served as VP of medical affairs at Medivation, where he played a key role in the development and commercialisation of enzalutamide for advanced prostate cancer. Earlier in his career, Dr Mansbach served as SVP of global drug development at Valeant Pharmaceuticals and Chief Medical Officer at Cortex Pharmaceuticals.
Dr Mansbach began his industry career at Glaxo Wellcome after clinical practice and research in neurology. He earned a medical degree from Duke University and a bachelor’s degree from Yale University.
Catherine Eckford is Editorial Assistant at European Pharmaceutical Review.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.